Three Biosimilar Barriers in Community Clinic
McKesson's Omar Hafez and Pete Perron discuss some of their takeaways working with biosimilars in the community clinic space.
From Clinical Use to Reimbursement
Dr. Robert Rifkin, medical director of biosimilars for McKesson, gives an update on biosimilar education and reimbursement.
Perfect Storm for Biosimilar Marketing
Dr. Robert Rifkin discusses the "perfect storm" for biosimilar marketing in a recent OncLive article.
Biosimilars: A Recent Review of Clinical Outcomes
A review of 14,000 individuals transitioned from a reference biologic medication to a biosimilar examines patient safety and treatment efficacy.
Overcoming Physician Barriers to Biosimilar Adoption in Clinics (PDF, 228 KB)
Omar Hafez shares how biopharmaceutical companies can learn how to overcome the clinical, operational, and economic barriers to biosimilar adoption.